Expensify's third quarter tells two stories, and only one of them is improving. The company reported a GAAP loss of $0.04 per share, wider than the $0.03 loss a year ago. That works out to a 33.3% year-over-year decline in earnings. Revenue fell 5.8% to $33.02 million. Management led with something else: a second consecutive increase to full-year free cash flow guidance, now $13.5 million to $15.5 million, up $1.5 million. It also highlighted New Expensify revenue up 30% sequentially and 212% year over year. That is the central tension. The growth engine is accelerating, but it is still too small to stop the consolidated top line from shrinking.

The quality of the quarter deserves scrutiny. Revenue slipped from roughly $33.9 million in Q2 and has now declined for several consecutive quarters. Cost of revenue rose to $18.1 million from $17.7 million despite lower sales. That pushed gross margin down to about 45% from nearly 50% a year earlier. Operating expenses fell by about $2 million, but the operating loss still widened to $2.7 million from $2.3 million. A $1.0 million tax provision, versus $0.15 million last year, added to the GAAP loss. On a non-GAAP basis the picture is softer as well:

• Adjusted EBITDA slipped to $6.1 million (18% margin) from $6.5 million (19%).
• Non-GAAP net income fell to $3.1 million from $4.3 million.

The year-to-date story is better than the quarter. Nine-month adjusted EBITDA margin rose to 19% from 13%, largely because sales and marketing spending was cut nearly in half. Most of the margin improvement came earlier in the year, however, and Q3 did not extend it.

The cash-flow narrative also needs context. Operating cash flow of $4.0 million compares with an outflow last year, which explains the eye-catching 510% increase. Q3 free cash flow of $3.3 million, however, was roughly half the $6.4 million generated in Q2. Year-to-date free cash flow of $12.2 million still trails last year's $16.6 million. The raised guidance implies only about $1.3 million to $3.3 million of fourth-quarter free cash flow. In effect, the raise largely reflects what has already been banked rather than an acceleration ahead.

The call preserved a credible growth story beneath the shrinking total. Net-new New Expensify ARR topped $13 million. That compares with just over $10 million cited in Q2 and about $7 million at the end of Q1. Management said newer cohorts convert better than older ones, and the release credits pipeline optimization with a 67% year-over-year improvement in cohort conversion. Travel posted a record quarter, with trips up 40% year over year and 13% sequentially. The newly launched consolidated travel billing should also lift revenue per booking. Paid members fell 2% year over year to 630,000, but October's 636,000 edged above July's 634,000. That suggests the base may be stabilizing, though it remains below the 641,000 reported in April.

The catalyst list is long. It includes Expensify Card issuance in GBP and EUR across 13 European markets, a referral agreement with Visa, and new ERP and HR integrations. Management also cited fast-growing MCP adoption tied to Anthropic's Claude for Small Business bundle. Some call details are less reliable: the transcript was heavily garbled, and partner names in the call notes do not fully match the release. Bears have legitimate ammunition elsewhere:

• Interchange growth decelerated to 8% ($5.8 million) from 12% in Q2, and dipped slightly in dollars sequentially.
• Buybacks shrank to about $1.3 million after Q2's much larger tender-driven reduction in share count.
• Management still cannot say when New Expensify growth will offset attrition in the declining Classic base.

Market context is thin for this report. No current price or sentiment reading was available. Shares opened at $2.17 after the August report, comfortably above the 200-day moving average near $1.62. That gap suggests investors had already been rewarding the cash-flow and New Expensify narrative heading into this quarter. Whether that support holds likely depends on evidence that revenue is nearing a bottom, not just on additional partnerships.

The bottom line is that Expensify is executing on the parts of the business it can control: costs, cash generation, product velocity, and New Expensify conversion. The consolidated numbers, however, still point the wrong way, with lower revenue, compressed gross margin, a wider GAAP loss, and slowing card growth. The FCF raise is real but backward-looking. Until New Expensify's ARR gains show up as a stabilizing top line, the turnaround remains a promising thesis rather than a demonstrated result.